Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
<p>Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retro...
Збережено в:
| Автор: | |
|---|---|
| Інші автори: | , , , , |
| Опубліковано: |
2025
|
| Предмети: | |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|